DAFTAR PUSTAKA

1. Paulsen F, Waschke J. *Sobotta Atlas Anatomi Manusia: Organ-Organ Dalam*. Edisi 23. Penerbit Buku Kedokteran EGC; 2015.
2. Sherwood L. *Fisiologi Manusia Dari Sel Ke Sistem*. Edisi 8. (Ong OH, Mahode AA, Ramadhani D, eds.). Penerbit Buku Kedokteran EGC; 2014.
3. Lin S-Z, Chang Y-J, Liu J-W, Chang L-F, Sun L-Y, Li Y-S, et al. Transplantation of Human Wharton's Jelly-Derived Stem Cells Alleviates Chemically Induced Liver Fibrosis in Rats. *Cell Transplant*. 2010;19(11):1451-1463.
4. Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. *Korean J Intern Med*. 2017;32(2):213-228.
5. Li B, Zhang C, Zhan Y-T. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. *Can J Gastroenterol Hepatol*. 2018;2018:1-8.
6. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet*. 2008;371(9615):838-851.
7. Sepanlou SG, Safiri S, Bisignano C, Ikuta K, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2020;5(3):245-266.
8. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The Epidemiology of Cirrhosis in the United States. *J Clin Gastroenterol*. 2015;49(8):690-696.
9. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. *J Hepatol*. 2013;58(3):593-608.
10. Kusumobroto H. *Sirosis Hati Dalam Buku Ajar Ilmu Penyakit Hati*. Edisi I. FK Universitas Indonesia; 2007.
11. Nurhadjah S. *Sirosis Hati Dalam Buku Ajar Ilmu Penyakit Dalam*. Edisi 4. Interna Publishing; 2014.
12. Zhou W-C. Pathogenesis of liver cirrhosis. *World J Gastroenterol*. 2014;20(23):7312.

13. Carvalho JR, Machado MV. New Insights About Albumin and Liver Disease. *Ann Hepatol*. 2018;17(4):547-560.
14. Zaccherini G, Bernardi M. The role and indications of albumin in advanced liver disease. *Acta Gastroenterol Belg*. 2019;82(2):301-308.
15. Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. *Korean J Intern Med*. 2015;30(5):580-589.
16. Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, et al. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. *Inflamm Regen*. 2019;39(1):18.
17. Stasi C, Silvestri C, Voller F, Cipriani F. Epidemiology of Liver Cirrhosis. *J Clin Exp Hepatol*. 2015;5(3):272.
18. Lovena A, Miro S, Efrida E. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2017;6(1):5.
19. Lefton HB, Rosa A, Cohen M. Diagnosis and Epidemiology of Cirrhosis. *Med Clin North Am*. 2009;93(4):787-799.
20. Scorza M, Elce A, Zarrilli F, Liguori R, Amato F, Castaldo G. Genetic Diseases That Predispose to Early Liver Cirrhosis. *Int J Hepatol*. 2014;2014:1-11.
21. Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. *Annu Rev Med*. 2016;67(1):103-117.
22. Sajja KC, Mohan DP, Rockey DC. Age and Ethnicity in Cirrhosis. *J Investig Med*. 2014;62(7):920-926.
23. Lurie Y. Non-invasive diagnosis of liver fibrosis and cirrhosis. *World J Gastroenterol*. 2015;21(41):11567.
24. Arthur MJP. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Liver Physiol*. 2000;279(2):G245-G249.
25. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005;115(2):209-218.
26. Altamirano-Barrera A, Barranco-Fragoso B, Méndez-Sánchez N. Management Strategies for Liver Fibrosis. *Ann Hepatol*. 2017;16(1):48-56.
27. Williams EJ, Iredale JP. Liver cirrhosis. *Postgrad Med J*. 1998;74(870):193-202.

28. Seo YS. Diagnosis of liver cirrhosis. *J Korean Med Assoc*. 2017;60(7):561.
29. Wai C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. 2003;38(2):518-526.
30. Toshikuni N. Nutrition and exercise in the management of liver cirrhosis. *World J Gastroenterol*. 2014;20(23):7286.
31. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. *J Hepatol*. 2004;40(4):646-652.
32. Campillo B, Richardet J-P, Scherman E, Bories PN. Evaluation of nutritional practice in hospitalized cirrhotic patients. *Nutrition*. 2003;19(6):515-521.
33. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. *Clin Nutr*. 2006;25(2):285-294.
34. Swart GR, Zillikens MC, van Vuure JK, van den Berg JW. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. *BMJ*. 1989;299(6709):1202-1203.
35. Hayashi F, Matsumoto Y, Momoki C, Yuikawa M, Okada G, Hamakawa E, et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. *Hepatol Res*. 2013;43(12):1264-1275.
36. Eom YW. Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. *World J Gastroenterol*. 2015;21(36):10253.
37. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. *Arch Iran Med*. 2007;10(4):459-466.
38. Meirelles Júnior RF, Salvalaggio P, Rezende MB de, Evangelista A, Guardia B, Matielo C, et al. Liver transplantation: history, outcomes and perspectives. *Einstein (São Paulo)*. 2015;13(1):149-152.
39. Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera J V, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. *J Clin Transl Hepatol*. 2020;8(1):1-7.

40. Wiegand J, Berg T. The Etiology, Diagnosis and Prevention of Liver Cirrhosis. *Dtsch Aerzteblatt Online*. Published online February 8, 2013.
41. Zein CO, Unalp A, Colvin R, Liu Y-C, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. *J Hepatol*. 2011;54(4):753-759.
42. Modi AA, Feld JJ, Park Y, Kleiner D, Everhart J, Liang T, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. *Hepatology*. 2010;51(1):201-209.
43. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther*. 2019;10(1):68.
44. Larijani B, Esfahani EN, Amini P, Nikbin B, Alimoghaddam K, Amiri S, et al. Stem cell therapy in treatment of different diseases. *Acta Med Iran*. 2012;50(2):79-96.
45. de Freitas Souza BS, Nogueira RC, de Oliveira SA, De Freitas L, Lyra L, Dos Santos R, et al. Current Status of Stem Cell Therapy for Liver Diseases. *Cell Transplant*. 2009;18(12):1261-1279.
46. Tang X-P. Differentiation of human umbilical cord blood stem cells into hepatocytes in vivo and in vitro. *World J Gastroenterol*. 2006;12(25):4014.
47. Ranjbaran H, Abediankenari S, Mohammadi M, Jafari N, Khalilian A, Rahmani Z, et al. Wharton's jelly derived-mesenchymal stem cells: Isolation and characterization. *Acta Med Iran*. 2018;56(1):28-33.
48. Fong C, Richards M, Manasi N, Biswas A, Bongso A. Comparative growth behaviour and characterization of stem cells from human Wharton's jelly. *Reprod Biomed Online*. 2007;15(6):708-718.
49. Wang H-S, Hung S-C, Peng S-T, Huang C-C, Wei H-M, Guo Y-J, et al. Mesenchymal Stem Cells in the Wharton's Jelly of the Human Umbilical Cord. *Stem Cells*. 2004;22(7):1330-1337.
50. Davies JE, Walker JT, Keating A. Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. *Stem Cells Transl Med*. 2017;6(7):1620-1630.
51. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. *Hepatology*. 1988;8(2):385-401.

52. Yuwen P, Chen W, Lv H, Feng C, Li Y, Zhang T, et al. Albumin and surgical site infection risk in orthopaedics: a meta-analysis. *BMC Surg*. 2017;17(1):7.
53. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. *Hepatology*. 2013;58(5):1836-1846.
54. Levitt D, Levitt M. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *Int J Gen Med*. 2016;Volume 9:229-255.
55. Bernardi M, Ricci CS, Zaccherini G. Role of Human Albumin in the Management of Complications of Liver Cirrhosis. *J Clin Exp Hepatol*. 2014;4(4):302-311.
56. Lee OK, Kuo TK, Chen W-M, Lee K-D, Hsieh S-L, Chen T-H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood*. 2004;103(5):1669-1675.
57. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization. Published online 2000.
58. Regimbeau J-M, Fuks D, Kohneh-Shahri N, Terris B, Soubrane O. Restrictive model of compensated carbon tetrachloride-induced cirrhosis in rats. *World J Gastroenterol*. 2008;14(45):6943.
59. Amin A, El-Mashed AB. Antifibrogenic effect of mesenchymal stem cells against thioacetamide-induced liver fibrosis in rats. *J Adv Vet Res*. 2020;10(3):117-125.
60. Lee KS, Lee SJ, Park HJ, Chung JP, Han KH, Chon CY, et al. Oxidative stress effect on the activation of hepatic stellate cells. *Yonsei Med J*. 2001;42(1):1.
61. Bak J, Je NK, Chung HY, Yokozawa T, Yoon S, Moon J-O. Oligonol Ameliorates CCl 4 -Induced Liver Injury in Rats via the NF-Kappa B and MAPK Signaling Pathways. *Oxid Med Cell Longev*. 2016;2016:1-12.